Numerous studies have demonstrated the effectiveness and safety of JAK-STAT inhibitors in CRC models, showing reduced tumor growth, increased therapeutic sensitivity, and enhanced immune responses (Chalikonda et al., 2021; Bajpai et al., 2024; Wu et al., 2024). This evidence concerns the gene SOAT1 and colorectal carcinoma.